A prominent mass tort marketing firm, Consumer Attorney Marketing Group (CAMG), has brought on board litigation finance expert Max Doyle to spearhead its expanding funding program. Doyle, who formerly served as CEO of litigation funder LexShares, joins CAMG as chief strategy officer. His primary focus will be on enhancing the company’s funder program, a division that now represents more than half of CAMG’s business.
Mass tort marketing specialists like CAMG typically assist law firms that handle mass tort and personal injury cases by generating leads through aggressive advertising campaigns on various media platforms. In a noteworthy shift, CAMG is partnering directly with litigation funders, connecting them with attorneys to facilitate lead generation. This trend underscores the increasing integration of funding entities into the mass tort marketing space.
According to Doyle, CAMG offers funders the opportunity to tailor their investment strategies, allowing them greater control over capital deployment. Instead of simply financing a law firm’s current cases, funders can allocate resources to develop new dockets through CAMG’s advertising efforts. This model often involves an intermediary firm to manage paperwork, accounting, and case acquisition, which in turn partners with law firms for litigation, with funding secured against these cases.
The recent changes in professional conduct rules in places like Arizona, which permit non-lawyers to own equity in law firms, are contributing to the evolving landscape of mass tort investments. These regulatory adjustments provide more robust options for mass tort funders to structure their portfolios. The influx of private equity and funders into states with more flexible rules, as highlighted in a report, exemplifies this shift.
California-based CAMG, operational for nearly 15 years, has established itself as a leading entity in mass tort marketing. Apart from lead generation, the firm offers services in public relations, medical record retrieval, and client intake. CEO Steve Nober noted that while the firm has been involved in significant dockets like those for Johnson & Johnson talcum powder and Camp Lejeune, current efforts are focused on litigation related to PFAs water contamination, Monsanto’s Round Up, and emerging cases involving weight-loss drug Ozempic.
Doyle emphasized the dual nature of mass tort litigation as both an investment opportunity and a vital means for consumers to challenge large corporations. His move to this sector marks a deliberate shift following challenges in the commercial litigation funding landscape, as his previous firm, LexShares, encountered delays and staff reductions. Doyle’s strategic approach aims to capitalize on the growing interest and investment in mass torts.
The full article detailing this development is available here.